Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity

BACKGROUND: Continuous infusion of doxorubicin has been a strategy to reduce cardiotoxicity. Epirubicin is another anthracycline in common clinical use. However, evidence is lacking regarding whether this strategy can reduce cardiotoxicity of epirubicin without compromising antineoplastic efficacy....

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fang, Lei, Qiao, Li, Lu, He, Jian Chang, Zeng, Jiajia, Luo, Chunxiang, Yeung, Sai-Ching Jim, Yang, Runxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683617/
https://www.ncbi.nlm.nih.gov/pubmed/29131861
http://dx.doi.org/10.1371/journal.pone.0188025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683617/
https://www.ncbi.nlm.nih.gov/pubmed/29131861
http://dx.doi.org/10.1371/journal.pone.0188025

Ejemplares similares